A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

⟵ Back to Search Results

Beigene Study ID

BGB-900-104

ClinicalTrials.gov ID

NCT03941873

China Drug Trials ID

CTR20182149

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents